HighPoint Advisor Group LLC Buys 12,908 Shares of Zoetis Inc. (NYSE:ZTS)

HighPoint Advisor Group LLC raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 106.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 25,001 shares of the company's stock after acquiring an additional 12,908 shares during the period. HighPoint Advisor Group LLC's holdings in Zoetis were worth $4,073,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Mission Wealth Management LP lifted its stake in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. boosted its position in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC boosted its stake in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after acquiring an additional 62 shares during the last quarter. Procyon Advisors LLC increased its stake in shares of Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after purchasing an additional 63 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its position in Zoetis by 6.6% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock worth $170,000 after buying an additional 65 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Remove Ads

Zoetis Price Performance

NYSE:ZTS traded down $4.16 during mid-day trading on Thursday, reaching $159.34. The stock had a trading volume of 3,271,279 shares, compared to its average volume of 2,601,809. The stock has a market capitalization of $71.35 billion, a P/E ratio of 29.13, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33. The firm has a 50 day moving average price of $166.20 and a two-hundred day moving average price of $173.98.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.26%. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

Insider Buying and Selling at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZTS shares. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Finally, StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.